Domicilium Real Estate Fund III LP 4

What Happened Domicilium Real Estate Fund III LP, a reported 10% holder of Eloxx Pharmaceuticals (ELOX), acquired common stock on June 10, 2026 by exchanging pre‑funded warrants for shares. The filing shows two conversions: 238,422 shares and 361,578 shares, for a total of 600,000 shares. No cash price is reported (transactions listed as N/A) because the shares were issued in exchange for pre‑funded warrants (see F1).

Key Details

• Transaction date: 2026-06-10 (reported on Form 4 filed 2026-06-17).
• Type: Acquisition via exchange of pre‑funded warrants (derivative conversion) (F1).
• Shares acquired: 238,422 and 361,578 (600,000 total). Price: N/A.
• Shares owned after transaction: not specified in the Form 4.
• Notable footnotes: securities are held directly by the Fund and may be indirectly beneficially owned by Domicilium Capital Partners LLC, Domicilium Real Estate Fund III GP LLC, Daniel Simon and related entities (F2–F7). Pre‑funded warrants have no expiration and include a ~19.99% ownership cap on exercise (F5). Reporting persons will be added on subsequent Form 4s once CIKs are received.
• Filing timeliness: No late‑filing indicator shown in this report.

Context This was an institutional conversion of pre‑funded warrants into common stock (not an open‑market purchase or a sale by an officer). For retail investors, note this reflects an institutional holder taking delivery of shares via conversion rather than buying on the market; it does not necessarily signal insider sentiment. The filing also includes typical disclaimers that the reporting entities may only claim pecuniary interests and that additional reporting persons will be listed later.